BIBF1120 Nintedanib CAS NO.928326-83-4 CAS NO.928326-83-4
- FOB Price: USD: 1.00-1.00 /Gram Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: L/C,D/A,D/P,T/T,MoneyGram,Other
- Available Specifications:
99%(1-100)Gram
- Product Details
Keywords
- Nintedanib supplier
- high purity Nintedanib
- Nintedanib monoethanesulfonate salt
Quick Details
- ProName: BIBF1120 Nintedanib CAS NO.928326-83-4
- CasNo: 928326-83-4
- Molecular Formula: C31H33N5O4
- Appearance: light yellow powder
- Application: pharmaceutical usage for lab use only
- DeliveryTime: 3 workingdays.
- PackAge: 1g/bag, 5g/bag, 10g/bag,
- Port: wuhan
- ProductionCapacity: 100 Gram/Month
- Purity: 99%
- Storage: in tight container
- Transportation: by air
- LimitNum: 1 Gram
- Related Substances: 0.1%
- Residue on Ignition: 0.5%
- Heavy Metal: NMT 20ppm
- Valid Period: 2 years
Superiority
Description |
White to light yellow powder |
Identification: |
HNMR: Meet the requirements |
Residual solvents |
Petroleum ether: NMT0.03%Dimethyl sulfoxide: NMT 0.5% Methylene chloride: NMT 0.06% methanol: NMT 0.3%Ethyl acetate: NMT 0.5%Ethanol: NMT 0.5% |
Heavy Metal |
NMT 20ppm |
Related substances |
Individual impurity:NMT 0.1%Total impurity:NMT 0.5% |
Assay |
NLT 99.0% |
We can offer Nintedanib free base and Nintedanib monoethanesulfonate salt.
Also we can offer Nintedanib intermediates for R&D to commericial quantities.
We can offer TDP documents for support.
Details
Description |
White to light yellow powder |
Identification: |
HNMR: Meet the requirements |
Residual solvents |
Petroleum ether: NMT0.03%Dimethyl sulfoxide: NMT 0.5% Methylene chloride: NMT 0.06% methanol: NMT 0.3%Ethyl acetate: NMT 0.5%Ethanol: NMT 0.5% |
Heavy Metal |
NMT 20ppm |
Related substances |
Individual impurity:NMT 0.1%Total impurity:NMT 0.5% |
Assay |
NLT 99.0% |
Wuhan Sunrise Technology Development Company limited(Wuhan Sunrise Pharmaceutical Tehcnology Co., Ltd) Wuhan Sunrise Technology Development Company limited is a high-tech pharmaceutical enterprise dedicated to R&D of chemical drug. The main business are R&D, technology transfer and technical services of APIs and pharmaceutical intermediates; R&D, manufacture and sales of PIs. Moreover, we have the right of dealing self-managed imp & exp business.
Main products:
Chemical synthesis series:
anti-cancer pharmaceutical intermediates,
ophthalmology APIs and related intermediates
Biological series: Mabs